/
JAZZ
$239.75+$2.03 (+0.85%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$14.4B
63M shares
52-week range
$105.00 – $243.32
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$58.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.89B | $2.16B | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B |
| Cost of revenue | $121.5M | $127.9M | $148.9M | $440.8M | $540.5M | $435.6M | $445.7M | $503.3M |
| Gross profit | $1.77B | $2.03B | $2.21B | $2.65B | $3.12B | $3.40B | $3.62B | $3.76B |
| Gross margin | 93.6% | 94.1% | 93.7% | 85.8% | 85.2% | 88.6% | 89.0% | 88.2% |
| R&D | $226.6M | $299.7M | $335.4M | $505.7M | $590.5M | $849.7M | $884.0M | $782.7M |
| Operating income | $614.8M | $532.4M | $378.1M | $170.3M | −$65.5M | $578.6M | $716.6M | $224.4M |
| EBITDA | $932.7M | $1.01B | $1.04B | $1.03B | $1.47B | $1.45B | $1.52B | $108.5M |
| Net income | $447.1M | $523.4M | $238.6M | −$329.0M | −$224.1M | $414.8M | $560.1M | −$356.1M |
| Net margin | 23.6% | 24.2% | 10.1% | -10.6% | -6.1% | 10.8% | 13.8% | -8.3% |
| EPS (diluted) | 7.30 | 9.09 | 4.22 | -5.51 | -3.58 | 6.10 | 8.65 | -5.84 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.5B | $25.37 | $24.09–$27.12 | 10 |
| 2027 | $4.8B | $25.75 | $23.33–$29.90 | 10 |
| 2028 | $5.3B | $29.66 | $21.28–$38.94 | 6 |
| 2029 | $5.8B | $32.70 | $31.12–$34.43 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$457.20
Price
$239.75
Implied upside
+91%
Peer comparison
Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
www.jazzpharmaceuticals.com- Employees
- 2,890
- IPO / List date
- Jun 1, 2007
- HQ
- DUBLIN
Held by traders on TradeandTell
No one on the platform currently holds JAZZ.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in JAZZ as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded JAZZ yet.
